3 completed, 1 withdrawn. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow Cell Therapy Catapult: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENgineered Tissue Repair of BronchopleUral FiSTula BPF-001 - Bronchopleural Fistula | Phase 1 / Phase 2 | Withdrawn | Videregen Limited | 2025-10-01 | 2025-04-01 | |
| A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome MultiStem, Placebo - Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Completed | Healios K.K. | 36 | 2016-01-01 | 2019-11-20 |
| A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients Autologous WT1 TCR transduced T cells - Myelodysplastic Syndromes (MDS), Acute Myeloid Leukaemia (AML) | Phase 1 / Phase 2 | Completed | Cell Medica Ltd | 3 | 2015-09-01 | 2018-10-02 |
| WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study WT1 TCR-transduced T cells - Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia | Phase 1 / Phase 2 | Completed | Cell Medica Ltd | 7 | 2012-04-01 | 2018-10-02 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myelodysplastic Syndromes (1) · Respiratory Distress Syndrome (1)
United Kingdom (3) · Belgium (1) · Germany (1) · United States (1)
Emma Morris, Dr (1) · Emma Morris, MD (1) · Geoff Bellingan, MD (1)